Antipsychotics Associated With an Increased Risk of Mortality in Elderly Patients

Risk of Death Now Linked with Atypical and Typical Antipsychotics

FDA notified healthcare professionals that both conventional and atypical antipsychotics are associated with an increased risk of mortality in elderly patients treated for dementia-related psychosis.

In April 2005, FDA notified healthcare professionals that patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death. Since issuing that notification, FDA has reviewed additional information that indicates the risk is also associated with conventional antipsychotics.

Antipsychotics are not indicated for the treatment of dementia-related psychosis. The prescribing information for all antipsychotic drugs will now include the same information about this risk in a BOXED WARNING and the WARNING section.

Legal Help

If you or a loved one has suffered ill health or damages while using these products, please click the link below to send your complaint to a lawyer to evaluate your claim at no cost or obligation.
Published on Jun-17-08